What Is the Prognostic Impact of (11;14) in Myeloma?

By Blood Cancer Talks - Last Updated: October 20, 2023

In this episode of “Blood Cancer Talks,” the hosts are joined by Rafael Fonseca, MD and Martin Kaiser, MD to discuss the biology and management of t(11;14) multiple myeloma and the role of venetoclax treatment.

They also discuss the natural history of t(11;14) myeloma in the era of proteasome inhibitors and immunomodulatory imide drugs before launching into the efficacy of Dara-VCD by cytogenetic subgroups in AL Amyloidosis, the phase I/II trial on daratumumab-venetoclax-dexamethasone in relapsed or refractory myeloma, and the BELLINI and CANOVA trials.

Plus, they highlight some of the historical studies that identified t(11;14) and its prognostic impact in myeloma.

This podcast originally appeared on Blood Cancer Talks. 

Advertisement
Advertisement
Advertisement
Editorial Board